|
|
| | PROTAC IRAK4 degrader-2 Basic information |
| Product Name: | PROTAC IRAK4 degrader-2 | | Synonyms: | PROTAC IRAK4 degrader-2;1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-4-{3-[9-(5-{[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}pyrimidin-2-yl)-3,9-diazaspiro[5.5]undecan-3-yl]prop-1-yn-1-yl}-7-methoxyisoquinoline-6-carboxamide | | CAS: | 2374122-27-5 | | MF: | C57H68FN11O8S | | MW: | 1086.29 | | EINECS: | | | Product Categories: | | | Mol File: | 2374122-27-5.mol |  |
| | PROTAC IRAK4 degrader-2 Chemical Properties |
| density | 1.40±0.1 g/cm3(Predicted) | | pka | 12.36±0.46(Predicted) |
| | PROTAC IRAK4 degrader-2 Usage And Synthesis |
| Uses | PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC50 in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC50 of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs[1]. | | IC 50 | IRAK4 | | References | [1] Joao Nunes, et al. Targeting IRAK4 for Degradation with PROTACs. ACS Med Chem Lett. 2019 Jun 14;10(7):1081-1085. DOI:10.1021/acsmedchemlett.9b00219 |
| | PROTAC IRAK4 degrader-2 Preparation Products And Raw materials |
|